Pfizer Hemophilia recently announced that the U.S. Food and Drug Administration approved the 3,000 IU dosage strength of BeneFIX®, a recombinant factor IX product indicated for the control, prevention and peri-operative management of bleeding episodes in adult and pediatric patients with hemophilia B.
According to Pfizer, the new dosage option will be available to patients in the coming months. Pfizer Hemophilia is the first to offer this new dosage strength for hemophilia B patients, providing reconstitution convenience for those taking 3,000 IU or higher dosage strengths.
Source: Pfizer
